Nuchal translucency and first trimester biochemical markers for Down syndrome screening: A cost-effectiveness analysis

被引:36
作者
Caughey, AB [1 ]
Kuppermann, M
Norton, ME
Washington, AE
机构
[1] Univ Calif San Francisco, Dept Obstet & Gynecol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Reprod Sci, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Med Effectiveness Res Ctr, San Francisco, CA 94143 USA
[4] Univ Calif Berkeley, Div Hlth Serv & Policy Anal, Berkeley, CA 94720 USA
关键词
prenatal testing; Down syndrome; cost-effectiveness analysis;
D O I
10.1067/mob.2002.127144
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: The purpose of this study was to perform a cost-effectiveness analysis that compared the first-and second-trimester screening tools for Down syndrome. STUDY DESIGN: A decision tree was designed that compared four possible screens for Down syndrome: (1) current second-trimester expanded maternal serum alpha-fetoprotein test (AFP), (2) first-trimester nuchal translucency screen, (3) first-trimester serum screen, and (4) combined first-trimester screen with both nuchal translucency screen and a serum screen. Incremental cost-benefit and cost-effectiveness ratios were calculated that compared the first-trimester screens with expanded alpha-fetoprotein. RESULTS: The combined screen (nuchal translucency screen + first-trimester serum screen) identified 3833 Down syndrome fetuses, the nuchal translucency alone identified 3413 Down syndrome fetuses, and the first-trimester serum screen identified 2993 Down syndrome fetuses. Each of these screens was an improvement over the current expanded AFP screen, which diagnosed 2446 Down syndrome fetuses. It would cost $98,381 for each additional Down syndrome case that would be identified by nuchal translucency alone, with a benefit-to-cost ratio of 4.85. The addition of the first-trimester serum screen is still cost-effective compared with expanded AFP; the cost would be $319,934 for each additional Down syndrome fetus who was identified, which would be a benefit-to-cost ratio of 1.57. CONCLUSION: First-trimester screening for Down syndrome with nuchal translucency screening alone or with serum markers is more clinically effective and cost-effective than the current expanded AFP screen that is being used.
引用
收藏
页码:1239 / 1245
页数:7
相关论文
共 48 条
[1]   Screening for Down's syndrome: Changes in marker levels and detection rates between first and second trimesters [J].
Berry, E ;
Aitken, DA ;
Crossley, JA ;
Macri, JN ;
Connor, JM .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 (07) :811-817
[2]  
BEWLEY S, 1995, BRIT J OBSTET GYNAEC, V102, P386, DOI 10.1111/j.1471-0528.1995.tb11290.x
[3]   First trimester screening for Down's syndrome using maternal serum PAPP-A and free β-hCG in combination with fetal nuchal translucency thickness [J].
Biagiotti, R ;
Brizzi, L ;
Periti, E ;
d'Agata, A ;
Vanzi, E ;
Cariati, E .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1998, 105 (08) :917-920
[4]  
BRIZOT ML, 1994, OBSTET GYNECOL, V84, P918
[5]   A PROSPECTIVE TRIAL OF PRENATAL SCREENING FOR DOWN-SYNDROME BY MEANS OF MATERNAL SERUM ALPHA-FETOPROTEIN, HUMAN CHORIONIC-GONADOTROPIN, AND UNCONJUGATED ESTRIOL [J].
BURTON, BK ;
PRINS, GS ;
VERP, MS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 169 (03) :526-530
[6]  
*CAL DEP HLTH SERV, 1997, PREN CAR PROV HDB
[7]  
CUCKLE HS, 1984, LANCET, V1, P926
[8]   ESTIMATING A WOMANS RISK OF HAVING A PREGNANCY ASSOCIATED WITH DOWNS-SYNDROME USING HER AGE AND SERUM ALPHA-FETOPROTEIN LEVEL [J].
CUCKLE, HS ;
WALD, NJ ;
THOMPSON, SG .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1987, 94 (05) :387-402
[9]  
De Biasio P, 1999, PRENATAL DIAG, V19, P360, DOI 10.1002/(SICI)1097-0223(199904)19:4<360::AID-PD556>3.0.CO
[10]  
2-U